Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mBio
    • Editor in Chief
    • Board of Editors
    • AAM Fellows
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
mBio
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mBio
    • Editor in Chief
    • Board of Editors
    • AAM Fellows
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ

Therapeutics and Prevention

  • Open Access
    Engineering of Long-Circulating Peptidoglycan Hydrolases Enables Efficient Treatment of Systemic <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> Infection
    Research Article | Therapeutics and Prevention
    Engineering of Long-Circulating Peptidoglycan Hydrolases Enables Efficient Treatment of Systemic Staphylococcus aureus Infection

    Life-threatening infections with Staphylococcus aureus are often difficult to treat due to the increasing prevalence of antibiotic-resistant bacteria and their ability to persist in protected niches in the body. Bacteriolytic enzymes are promising new antimicrobials because they rapidly kill bacteria, including drug-resistant and persisting cells, by destroying their...

    Anna M. Sobieraj, Markus Huemer, Léa V. Zinsli, Susanne Meile, Anja P. Keller, Christian Röhrig, Fritz Eichenseher, Yang Shen, Annelies S. Zinkernagel, Martin J. Loessner, Mathias Schmelcher
  • Open Access
    Outer Membrane Disruption Overcomes Intrinsic, Acquired, and Spontaneous Antibiotic Resistance
    Research Article | Therapeutics and Prevention
    Outer Membrane Disruption Overcomes Intrinsic, Acquired, and Spontaneous Antibiotic Resistance

    The spread of antibiotic resistance is an urgent threat to global health that necessitates new therapeutics. Treatments for Gram-negative pathogens are particularly challenging to identify due to the robust outer membrane permeability barrier in these organisms. Recent discovery efforts have attempted to overcome this hurdle by disrupting the outer membrane using chemical perturbants and have yielded several new peptides and small...

    Craig R. MacNair, Eric D. Brown
  • Open Access
    CD4<sup>+</sup> T Cell-Mimicking Nanoparticles Broadly Neutralize HIV-1 and Suppress Viral Replication through Autophagy
    Research Article | Therapeutics and Prevention
    CD4+ T Cell-Mimicking Nanoparticles Broadly Neutralize HIV-1 and Suppress Viral Replication through Autophagy

    HIV-1 is a major global health challenge. The development of an effective vaccine and/or a therapeutic cure is a top priority. The creation of vaccines that focus an antibody response toward a particular epitope of a protein has shown promise, but the genetic diversity of HIV-1 hinders this progress. Here we developed an approach using nanoengineered CD4+ T cell membrane-coated nanoparticles (TNP). Not only do TNP effectively...

    Gang Zhang, Grant R. Campbell, Qiangzhe Zhang, Erin Maule, Jonathan Hanna, Weiwei Gao, Liangfang Zhang, Stephen A. Spector
  • Open Access
    Unstable Mechanisms of Resistance to Inhibitors of <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Lipoprotein Signal Peptidase
    Research Article | Therapeutics and Prevention
    Unstable Mechanisms of Resistance to Inhibitors of Escherichia coli Lipoprotein Signal Peptidase

    Despite increasing evidence suggesting that antibiotic heteroresistance can lead to treatment failure, the significance of this phenomena in the clinic is not well understood, because many clinical antibiotic susceptibility testing approaches lack the resolution needed to reliably classify heteroresistant strains. Here we present G0790, a new globomycin analog and potent inhibitor of the...

    Homer Pantua, Elizabeth Skippington, Marie-Gabrielle Braun, Cameron L. Noland, Jingyu Diao, Yutian Peng, Susan L. Gloor, Donghong Yan, Jing Kang, Anand Kumar Katakam, Janina Reeder, Georgette M. Castanedo, Keira Garland, Laszlo Komuves, Meredith Sagolla, Cary D. Austin, Jeremy Murray, Yiming Xu, Zora Modrusan, Min Xu, Emily J. Hanan, Sharookh B. Kapadia
  • Open Access
    A Novel High-Potency Tetanus Vaccine
    Editor's Pick Research Article | Therapeutics and Prevention
    A Novel High-Potency Tetanus Vaccine

    Chemical inactivation is a clinically effective mechanism to detoxify protein toxins to produce vaccines against microbial infections and to serve as a platform for production of conjugate polysaccharide vaccines. This method is widely used for the production of protein toxin vaccines, including tetanus toxoid. However, chemical modification alters the protein structure with unknown effects on antigenicity. Here, a recombinant full-...

    Amanda Przedpelski, William H. Tepp, Sabine Pellett, Eric A. Johnson, Joseph T. Barbieri
  • Open Access
    Phage-Antibiotic Synergy Is Driven by a Unique Combination of Antibacterial Mechanism of Action and Stoichiometry
    Research Article | Therapeutics and Prevention
    Phage-Antibiotic Synergy Is Driven by a Unique Combination of Antibacterial Mechanism of Action and Stoichiometry

    Bacteriophage (phage) therapy is a promising approach to combat the rise of multidrug-resistant bacteria. Currently, the preferred clinical modality is to pair phage with an antibiotic, a practice thought to improve efficacy. However, antagonism between phage and antibiotics has been reported, the choice of phage and antibiotic is not often empirically determined, and the effect of the host factors on the effectiveness is unknown. Here...

    Carmen Gu Liu, Sabrina I. Green, Lorna Min, Justin R. Clark, Keiko C. Salazar, Austen L. Terwilliger, Heidi B. Kaplan, Barbara W. Trautner, Robert F. Ramig, Anthony W. Maresso
  • Open Access
    Novel Antimicrobials from Uncultured Bacteria Acting against <span class="named-content genus-species" id="named-content-1">Mycobacterium tuberculosis</span>
    Research Article | Therapeutics and Prevention
    Novel Antimicrobials from Uncultured Bacteria Acting against Mycobacterium tuberculosis

    Decreasing discovery rates and increasing resistance have underscored the need for novel therapeutic options to treat Mycobacterium tuberculosis infection. Here, we screen extracts from previously uncultured soil microbes for specific activity against Mycobacterium tuberculosis, identifying three...

    Jeffrey Quigley, Aaron Peoples, Asel Sarybaeva, Dallas Hughes, Meghan Ghiglieri, Catherine Achorn, Alysha Desrosiers, Cintia Felix, Libang Liang, Stephanie Malveira, William Millett, Anthony Nitti, Baldwin Tran, Ashley Zullo, Clemens Anklin, Amy Spoering, Losee Lucy Ling, Kim Lewis
  • Open Access
    An Entry-Triggering Protein of <em>Ehrlichia</em> Is a New Vaccine Candidate against Tick-Borne Human Monocytic Ehrlichiosis
    Research Article | Therapeutics and Prevention
    An Entry-Triggering Protein of Ehrlichia Is a New Vaccine Candidate against Tick-Borne Human Monocytic Ehrlichiosis

    The incidence of tick-borne diseases has risen dramatically in the past two decades and continues to rise. Discovered in 1986 and designated a nationally notifiable disease in 1998 by the Centers for Disease Control and Prevention, human monocytic ehrlichiosis, which is caused by the bacterium Ehrlichia chaffeensis, is one of the most prevalent, life-threatening,...

    Khemraj Budachetri, Omid Teymournejad, Mingqun Lin, Qi Yan, Mariella Mestres-Villanueva, Guy Nathaniel Brock, Yasuko Rikihisa
  • Open Access
    An Antivirulence Approach for Preventing <span class="named-content genus-species" id="named-content-1">Cryptococcus neoformans</span> from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease
    Research Article | Therapeutics and Prevention
    An Antivirulence Approach for Preventing Cryptococcus neoformans from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease

    Fungal infections like cryptococcal meningitis are difficult to resolve because of the limited therapies available. The small arsenal of antifungal drugs reflect the difficulty in finding available targets in fungi because like mammalian cells, fungi are eukaryotes. The limited efficacy, toxicity, and rising resistance of antifungals contribute to the high morbidity and mortality of fungal infections and further underscore the dire but...

    Phylicia A. Aaron, Kiem Vu, Angie Gelli
  • Open Access
    New Multidrug Efflux Inhibitors for Gram-Negative Bacteria
    Research Article | Therapeutics and Prevention
    New Multidrug Efflux Inhibitors for Gram-Negative Bacteria

    Multidrug-resistant Gram-negative bacteria pose a serious threat to human and animal health. Molecules that inhibit multidrug efflux offer an alternative approach to resolving the challenges caused by antibiotic resistance, by potentiating the activity of old, licensed, and new antibiotics. We have developed, validated, and implemented a high-throughput screen and used it to identify efflux inhibitors from two compound libraries...

    Robert L. Marshall, Georgina S. Lloyd, Amelia J. Lawler, Sarah J. Element, Jaswant Kaur, Maria Laura Ciusa, Vito Ricci, Andreas Tschumi, Holger Kühne, Luke J. Alderwick, Laura J. V. Piddock

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13
Back to top

About

  • About mBio
  • Editor in Chief
  • Board of Editors
  • AAM Fellows
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Author Warranty
  • Article Types
  • Ethics
  • Contact Us

Follow #mBio

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Online ISSN: 2150-7511